Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy

Autor: Harm van Tinteren, Kate Haslett, Astrid Keijser, Annija van der Leest, Egbert F. Smit, Bart Reymen, Matthew Hatton, Suresh Senan, Iris E. van Dam, Jos A. Stigt, Ben J. Slotman, J. Knegjens, Corinne Faivre-Finn, Devashish Tripathi, J. Praag

Publikováno v: Lung Cancer, 108, 150-153. ELSEVIER IRELAND LTD
Lung Cancer, 108, 150-153. Elsevier Ireland Ltd
Slotman, B J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J, Haslett, K, Tripathi, D, Smit, E F & Senan, S 2017, ' Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : A secondary analysis of the Phase III CREST trial ', Lung Cancer, vol. 108, pp. 150-153 . https://doi.org/10.1016/j.lungcan.2017.03.007
Slotman, B J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J O, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J A, Haslett, K, Tripathi, D, Smit, E F & Senan, S 2017, ' Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : A secondary analysis of the Phase III CREST trial ', Lung Cancer, vol. 108, pp. 150–153 . https://doi.org/10.1016/j.lungcan.2017.03.007

Introduction: In ES-SCLC patients with residual intrathoracic disease after first-line chemotherapy, the addition of thoracic radiotherapy reduces the risk of intrathoracic recurrence, and improves 2-year survival. To identify patient subgroups for f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::322dbaafe60a7267b7e96cab79b0469c
http://www.scopus.com/inward/record.url?scp=85016770261&partnerID=8YFLogxK